BioReference executes COVID-19 testing program for NBA and NHL for 2020-21 seasons, as well as U.S. Women’s and Men’s National Soccer Teams, Winter X Games and NBA G League
ELMWOOD PARK, N.J., 26 de enero de 2021 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced COVID-19 testing agreements for players and officials, as well as team and league staff for the 2020-2021 seasons for the National Basketball Association (NBA) and National Hockey League (NHL).
For the 2020-21 NBA season, BioReference has been providing testing services, utilizing PCR and rapid diagnostics, at the 30 NBA team facilities in 28 cities across the U.S. BioReference previously supported the NBA’s 2019-20 season restart.
Under an agreement with the NHL, BioReference will provide COVID-19 testing to players, coaches, staff and officials, which includes COVID-19 PCR laboratory-based diagnostics, and rapid diagnostics to the 24 U.S.-based teams.
In addition, BioReference is currently supporting the Winter X Games in Aspen, U.S. Soccer’s Women’s and Men’s National Teams and the NBA G League in Orlando.
“Continuing to support the NBA in the 2020-21 season, showcases lessons learned from Orlando, and leverages emerging technology to support the current season and the overall partnership we have built throughout the COVID-19 pandemic,” said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. “Utilizing similar detailed and systematic protocols, we have been selected to support the NHL, U.S. Soccer, Winter X Games and NBA G League. It is a privilege for BioReference to support professional sports, underscoring our commitment to develop customized solutions that assist Americans in getting back to the workplace safely and provide the nation access to entertainment.”
Información acerca de BioReference Laboratories, Inc.
BioReference provides comprehensive testing to physicians, clinics, hospitals, employers, government units, correctional institutions, and medical groups. BioReference developed and offers test services that yield high quality and accurate results, including a molecular test for helping with COVID-19 diagnosis and a serology test to help indicate possible COVID-19 exposure. La compañía trabaja en red con los cinco planes de salud más grandes de los Estados Unidos, dirige una red de 11 laboratorios y cuenta con el respaldo de un personal médico de más de 120 médicos, doctorados y demás clínicos y científicos de nivel profesional. With a leading position in the areas of genetics, women’s health, maternal fetal medicine, oncology, and urology, BioReference and its specialty laboratories, GenPath and GeneDx, are advancing the course of modern medicine. Para obtener más información, visite www.bioreference.com.
Información acerca de OPKO Health, Inc.
OPKO es una compañía biofarmacéutica y de diagnóstico multinacional que busca posicionarse como líder de la industria en grandes mercados de rápido crecimiento, a través de sus tecnologías exclusivas y su experiencia e innovación en el descubrimiento, el desarrollo y la comercialización. Para obtener más información, visite www.opko.com.
Advertencia respecto de declaraciones con perspectivas de futuro
This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning, including statements regarding the role and value of testing, whether the results from our previous testing program can be successfully duplicated or deployed in other settings or venues, whether implementing the same strategies or other strategies will be successful in preventing the spread of the disease or providing safety against infection to the participants, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, and strategies. Muchos factores podrían hacer que nuestras actividades o resultados reales difieran sustancialmente de las actividades y resultados anticipados en las declaraciones con perspectivas de futuro. Estos factores incluyen aquellos descritos en los informes anuales de OPKO Health, Inc. los informes anuales del formulario 10-K de OPKO Health, Inc. presentados y a presentarse ante la Comisión de Bolsa y Valores y en otras presentaciones nuestras ante la Comisión de Bolsa y Valores. Además, las declaraciones con perspectivas de futuro también pueden verse afectadas de manera adversa por factores generales del mercado, desarrollo de productos de la competencia, disponibilidad de productos, normas y leyes federales y estatales, el proceso regulatorio de nuevos productos e indicaciones, problemas de fabricación que puedan surgir, posiciones de patentes y litigios, entre otros factores. Las proyecciones que contiene este comunicado de prensa solo expresan la situación a la fecha en que se realizaron, y no asumimos obligación alguna de actualizar las proyecciones. Tenemos la intención de que todas las declaraciones con perspectivas de futuro estén sujetas a las disposiciones de puerto seguro de la ley PSLRA.
Contacto con los medios:
Hillary Titus, 201-406-9968
htitus@bioreference.com